DGAP-Adhoc

Merck KGaA: Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry - Seite 3

to product-related crime and espionage; risks in relation to the use of
financial instruments; liquidity risks; counterparty risks; market risks;
risks of impairment on balance sheet items; risks from pension obligations;
risks from product-related and patent law disputes; risks from antitrust
law proceedings; risks from drug pricing by the divested Generics Group;
risks in human resources; risks from e-crime and cyber attacks; risks due
to failure of business-critical information technology applications or to
failure of data center capacity; environmental and safety risks;
unanticipated contract or regulatory issues; a potential downgrade in the
rating of the indebtedness of Merck KGaA, Darmstadt, Germany, or
Sigma-Aldrich; downward pressure on the common stock price of Merck KGaA,
Darmstadt, Germany, or Sigma-Aldrich and its impact on goodwill impairment
evaluations; the impact of future regulatory or legislative actions; and
the risks and uncertainties detailed by Sigma-Aldrich with respect to its
business as described in its reports and documents filed with the U.S.
Securities and Exchange Commission (the 'SEC').

The foregoing review of important factors should not be construed as
exhaustive and should be read in conjunction with the other cautionary
statements that are included elsewhere, including the Report on Risks and
Opportunities Section of the most recent annual report and quarterly report
of Merck KGaA, Darmstadt, Germany, and the Risk Factors section of
Sigma-Aldrich's most recent reports on Form 10-K and Form 10-Q. Any
forward-looking statements made in this communication are qualified in
their entirety by these cautionary statements, and there can be no
assurance that the actual results or developments anticipated by us will be
realized or, even if substantially realized, that they will have the
expected consequences to, or effects on, us or our business or operations.
Except to the extent required by applicable law, we undertake no obligation
to update publicly or revise any forward-looking statement, whether as a
result of new information, future developments or otherwise.

Important Additional Information

This communication is being made in respect of the proposed merger
transaction involving Sigma-Aldrich and Merck KGaA, Darmstadt, Germany. The
proposed merger will be submitted to the stockholders of Sigma-Aldrich for
their consideration. In connection therewith, Sigma-Aldrich intends to file
relevant materials with the SEC, including a preliminary proxy statement